Literature DB >> 12955026

Growth hormone (GH) status and body composition in normal ageing and in elderly adults with GH deficiency.

Andrew A Toogood1.   

Abstract

Similarities have been observed between the changes associated with ageing and the symptoms of growth hormone (GH) deficiency. Changes such as increased fat mass and decreased muscle mass occur both in GH-deficient patients and in otherwise healthy elderly individuals. Moreover, ageing is associated with decreasing GH and insulin-like growth factor I (IGF-I) levels. It has been suggested, therefore, that hypothalamic-pituitary disease leading to GH deficiency (GHD) in elderly patients would have less impact than in younger adults. Studies suggest that healthy elderly individuals have normal pituitary reserves of GH, but that spontaneous GH secretion falls by around 14% per decade of adult life, leading to a state of functional GH insufficiency. Despite this, elderly patients with GHD experience reductions in GH secretion and IGF-I levels, compared with controls, which are of similar magnitude to those seen in younger GH-deficient adults. The metabolic changes associated with GHD are also seen in elderly patients compared with healthy elderly controls. Fat mass, particularly in the abdominal region, is significantly increased, with a strong correlation between fat mass and body mass index. Markers of bone formation and resorption are significantly reduced in the GH-deficient patients. Elderly adults who have hypothalamic-pituitary disease have a degree of GHD that can be distinguished from the decline in GH and IGF-I levels that is seen with normal ageing. GHD in elderly patients leads to significant changes in body composition and bone. Thus, these patients are likely to benefit from GH replacement therapy. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955026     DOI: 10.1159/000071234

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  8 in total

1.  Dehydroepiandrosterone restoration of growth hormone gene expression in aging female rats, in vivo and in vitro: evidence for actions via estrogen receptors.

Authors:  Mary Iruthayanathan; Yi-Hong Zhou; Gwen V Childs
Journal:  Endocrinology       Date:  2005-09-08       Impact factor: 4.736

Review 2.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

Review 3.  Crosstalk between the circadian clock circuitry and the immune system.

Authors:  Nicolas Cermakian; Tanja Lange; Diego Golombek; Dipak Sarkar; Atsuhito Nakao; Shigenobu Shibata; Gianluigi Mazzoccoli
Journal:  Chronobiol Int       Date:  2013-05-22       Impact factor: 2.877

4.  Resolving the Two "Bony" Faces of PPAR-gamma.

Authors:  Beata Lecka-Czernik; Larry J Suva
Journal:  PPAR Res       Date:  2006       Impact factor: 4.964

5.  Statistical methodology for age-adjustment of the GH-2000 score detecting growth hormone misuse.

Authors:  Dankmar Böhning; Walailuck Böhning; Nishan Guha; David A Cowan; Peter H Sönksen; Richard I G Holt
Journal:  BMC Med Res Methodol       Date:  2016-10-28       Impact factor: 4.615

Review 6.  Evidence for the Contribution of Gut Microbiota to Age-Related Anabolic Resistance.

Authors:  Matthew D Watson; Brett L Cross; Gregory J Grosicki
Journal:  Nutrients       Date:  2021-02-23       Impact factor: 5.717

Review 7.  Aging versus youth: Endocrine aspects of vulnerability for COVID-19.

Authors:  Seda Hanife Oguz; Meltem Koca; Bulent Okan Yildiz
Journal:  Rev Endocr Metab Disord       Date:  2021-04-16       Impact factor: 9.306

8.  Pharmacologic approaches to the aging athlete.

Authors:  John M Tokish; Daniel C Derosa
Journal:  Sports Health       Date:  2014-01       Impact factor: 3.843

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.